261 related articles for article (PubMed ID: 8555169)
1. Position-specific effects of base mismatch on mammalian topoisomerase II DNA cleaving activity.
Bigioni M; Zunino F; Tinelli S; Austin CA; Willmore E; Capranico G
Biochemistry; 1996 Jan; 35(1):153-9. PubMed ID: 8555169
[TBL] [Abstract][Full Text] [Related]
2. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
Spitzner JR; Chung IK; Gootz TD; McGuirk PR; Muller MT
Mol Pharmacol; 1995 Aug; 48(2):238-49. PubMed ID: 7651357
[TBL] [Abstract][Full Text] [Related]
3. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180).
Cornarotti M; Tinelli S; Willmore E; Zunino F; Fisher LM; Austin CA; Capranico G
Mol Pharmacol; 1996 Dec; 50(6):1463-71. PubMed ID: 8967966
[TBL] [Abstract][Full Text] [Related]
4. Drug-specific sites of topoisomerase II DNA cleavage in Drosophila chromatin: heterogeneous localization and reversibility.
Borgnetto ME; Zunino F; Tinelli S; Kas E; Capranico G
Cancer Res; 1996 Apr; 56(8):1855-62. PubMed ID: 8620504
[TBL] [Abstract][Full Text] [Related]
5. DNA sequence preferences at sites cleaved by human DNA topoisomerase II in response to novel quinolone derivatives.
Huff AC; Robinson RG; Evans AC; Selander KN; Wentland MP; Rake JB; Coughlin SA
Anticancer Drug Des; 1995 Apr; 10(3):251-76. PubMed ID: 7748459
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene.
Pommier Y; Orr A; Kohn KW; Riou JF
Cancer Res; 1992 Jun; 52(11):3125-30. PubMed ID: 1317259
[TBL] [Abstract][Full Text] [Related]
7. Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II.
Capranico G; De Isabella P; Tinelli S; Bigioni M; Zunino F
Biochemistry; 1993 Mar; 32(12):3038-46. PubMed ID: 8384486
[TBL] [Abstract][Full Text] [Related]
8. Application of a degenerate consensus sequence to quantify recognition sites by vertebrate DNA topoisomerase II.
Spitzner JR; Muller MT
J Mol Recognit; 1989 Sep; 2(2):63-74. PubMed ID: 2561527
[TBL] [Abstract][Full Text] [Related]
9. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
10. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
[TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro stimulation by antitumor drugs of the topoisomerase II-induced cleavage sites in c-myc proto-oncogene.
Riou JF; Vilarem MJ; Larsen CJ; Multon E; Riou GF
NCI Monogr; 1987; (4):41-7. PubMed ID: 2819730
[TBL] [Abstract][Full Text] [Related]
12. Linkage of a triple helix-forming oligonucleotide to amsacrine-4-carboxamide derivatives modulates the sequence-selectivity of topoisomerase II-mediated DNA cleavage.
Arimondo P; Bailly C; Boutorine A; Asseline U; Sun JS; Garestier T; Hélène C
Nucleosides Nucleotides Nucleic Acids; 2000 Aug; 19(8):1205-18. PubMed ID: 11097051
[TBL] [Abstract][Full Text] [Related]
13. Effects of base mutations on topoisomerase II DNA cleavage stimulated by mAMSA in short DNA oligomers.
Capranico G; Tinelli S; Zunino F; Kohn KW; Pommier Y
Biochemistry; 1993 Jan; 32(1):145-52. PubMed ID: 8380330
[TBL] [Abstract][Full Text] [Related]
14. Genomic sites of topoisomerase II activity determined by comparing DNA breakage enhanced by three distinct poisons.
Borgnetto ME; Tinelli S; Carminati L; Capranico G
J Mol Biol; 1999 Jan; 285(2):545-54. PubMed ID: 9878428
[TBL] [Abstract][Full Text] [Related]
15. Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded DNA cleavage.
Bromberg KD; Burgin AB; Osheroff N
Biochemistry; 2003 Apr; 42(12):3393-8. PubMed ID: 12653542
[TBL] [Abstract][Full Text] [Related]
16. Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents.
Hsiung Y; Jannatipour M; Rose A; McMahon J; Duncan D; Nitiss JL
Cancer Res; 1996 Jan; 56(1):91-9. PubMed ID: 8548781
[TBL] [Abstract][Full Text] [Related]
17. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
18. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone.
Drake FH; Hofmann GA; Mong SM; Bartus JO; Hertzberg RP; Johnson RK; Mattern MR; Mirabelli CK
Cancer Res; 1989 May; 49(10):2578-83. PubMed ID: 2540903
[TBL] [Abstract][Full Text] [Related]
19. Base mutation analysis of topoisomerase II-idarubicin-DNA ternary complex formation. Evidence for enzyme subunit cooperativity in DNA cleavage.
Bigioni M; Zunino F; Capranico G
Nucleic Acids Res; 1994 Jun; 22(12):2274-81. PubMed ID: 8036155
[TBL] [Abstract][Full Text] [Related]
20. Fluorometric assays for DNA topoisomerases and topoisomerase-targeted drugs: quantitation of catalytic activity and DNA cleavage.
Andrea JE; Adachi K; Morgan AR
Mol Pharmacol; 1991 Oct; 40(4):495-501. PubMed ID: 1656189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
